Q1 Earnings Estimate for RVMD Issued By HC Wainwright

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Revolution Medicines in a research note issued to investors on Thursday, August 27th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($2.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $280.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.82) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q2 2027 earnings at ($1.70) EPS, Q3 2027 earnings at ($1.62) EPS, Q4 2027 earnings at ($1.47) EPS and FY2027 earnings at ($6.86) EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the firm posted ($1.31) earnings per share.

A number of other analysts also recently issued reports on the company. Guggenheim raised their price target on Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Sanford C. Bernstein boosted their price objective on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. TD Cowen raised shares of Revolution Medicines to a “strong-buy” rating in a research note on Monday. Wolfe Research restated an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Finally, Mizuho raised their target price on shares of Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $193.28.

Revolution Medicines Stock Performance

NASDAQ RVMD opened at $221.15 on Friday. The company has a market cap of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The business’s 50 day moving average price is $192.43 and its 200-day moving average price is $148.17. Revolution Medicines has a fifty-two week low of $37.56 and a fifty-two week high of $224.31.

Institutional Trading of Revolution Medicines

Several institutional investors and hedge funds have recently made changes to their positions in the business. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines during the second quarter valued at $32,000. Global Retirement Partners LLC increased its stake in Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the period. Torren Management LLC purchased a new position in Revolution Medicines in the 4th quarter worth about $33,000. Johnson Financial Group Inc. bought a new stake in Revolution Medicines during the 2nd quarter valued at about $37,000. Finally, Arax Advisory Partners bought a new stake in Revolution Medicines during the 4th quarter valued at about $38,000. 94.34% of the stock is currently owned by institutional investors.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the transaction, the chief financial officer owned 123,269 shares of the company’s stock, valued at $20,749,870.77. This represents a 13.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the completion of the transaction, the director directly owned 21,656 shares in the company, valued at $4,071,111.44. This trade represents a 20.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 212,497 shares of company stock valued at $38,206,486. Company insiders own 7.60% of the company’s stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial catalyst. RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, potentially establishing a new treatment option for patients with limited alternatives. FDA approval announcement
• Positive Sentiment: Analysts remain bullish after the approval. HC Wainwright reiterated a “Buy” rating and a $280 price target, above the referenced $221.15 price, while forecasting a narrower FY2027 loss of $6.86 per share. Truist also raised its target to $239 and Wedbush increased its target to $225, both maintaining positive ratings.
• Positive Sentiment: Early launch expectations are favorable. RBC reportedly views the RASONQUE launch as capable of moving quickly, while Oppenheimer said the product’s label expands Revolution Medicines’ commercial opportunity. The company’s decision to remain independent could allow shareholders to retain greater value from the drug’s potential.
• Neutral Sentiment: Near-term financial results will still reflect a development-stage business. HC Wainwright projects quarterly 2027 losses of $2.06, $1.70, $1.62 and $1.47 per share, for a full-year loss of $6.86 per share. Investors are likely to focus on prescription trends, reimbursement and initial revenue after the launch.
• Negative Sentiment: RASONQUE’s $39,800 monthly price may create access and reimbursement risks. Although the price supports substantial revenue potential, it could attract scrutiny from payers and policymakers or slow patient access, tempering some of the enthusiasm surrounding the FDA decision. RASONQUE pricing article

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.